The estimated Net Worth of Thomas P Castellano is at least $2.76 Million dollars as of 24 August 2022. Mr Castellano owns over 1,414 units of Catalent stock worth over $1,198,503 and over the last 3 years he sold CTLT stock worth over $829,129. In addition, he makes $731,916 as Sr. VP & CFO at Catalent.
Mr has made over 5 trades of the Catalent stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,414 units of CTLT stock worth $145,699 on 24 August 2022.
The largest trade he's ever made was selling 2,307 units of Catalent stock on 20 October 2021 worth over $309,138. On average, Mr trades about 1,119 units every 66 days since 2021. As of 24 August 2022 he still owns at least 20,099 units of Catalent stock.
You can see the complete history of Mr Castellano stock trades at the bottom of the page.
Thomas P. Castellano is the Sr. VP & CFO at Catalent.
As the Sr. VP & CFO of Catalent, the total compensation of Mr Castellano at Catalent is $731,916. There are 10 executives at Catalent getting paid more, with John Chiminski having the highest compensation of $8,514,990.
Mr Castellano is 41, he's been the Sr. VP & CFO of Catalent since . There are 26 older and no younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius und Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: